Semaglutide shown to delay first-hour gastric emptying in people with obesity

A study led by researcher C. Hjerpsted and colleagues, published in October 2017, found that semaglutide slows the movement of food out of the stomach during the first hour after a meal in people with obesity, but that overall stomach emptying over a longer period was similar to placebo ^[1].

The researchers measured this using a marker drug, acetaminophen, which is absorbed from the small intestine rather than the stomach. When someone takes acetaminophen with a meal, how quickly it shows up in the blood reflects how quickly food is leaving the stomach. In this study, the ratio of acetaminophen exposure (measured as area under the curve, or AUC) in people taking semaglutide compared to those taking placebo was 0.73 in the first hour, meaning less acetaminophen reached the bloodstream early on, a sign of slower initial gastric emptying ^[1]. Beyond that early window, the difference between semaglutide and placebo narrowed, and total emptying over the full test period looked similar between the two groups ^[1].

This pattern, a temporary slowdown early after eating rather than a constant, ongoing delay, has become a reference point for how semaglutide's gastric effects are described. According to the source, this 2017 finding continues to underpin how the drug's label describes its effect on stomach emptying ^[1].

Why it matters for patients

Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus. One reason these drugs help people feel full and eat less is that they affect how the stomach handles food. This study suggests that effect is strongest right after a meal rather than being a steady, all-day slowdown ^[1].

For patients, this distinction can matter when thinking about timing of meals, other medications taken by mouth, or side effects like nausea and fullness that tend to cluster around eating. Because the drug's effect on emptying is described as concentrated in the early period after a meal rather than persisting for hours, it may help explain why some symptoms are tied closely to when someone eats ^[1].

The source does not describe how this early, short-term slowing might change over weeks or months of continued treatment, whether it differs by dose, or whether it explains all of the drug's effect on appetite and food intake. Those details are not addressed in the material available here.

What happens next

The source provided does not include newer dates, follow-up studies, or updates on this finding, so it is not known from this material whether later research has confirmed, expanded, or changed this original description of semaglutide's effect on gastric emptying. What is documented is that this 2017 study remains the basis referenced for how the drug's label currently describes the gastric emptying effect ^[1].

People who want more detail on how semaglutide's gastric effects are currently described, or on how this early finding has been incorporated into more recent research, would need to look at additional sources beyond what is available here, since this material does not go further than the original 2017 report.